How is Abrocitinib Synthesized?
The synthesis of abrocitinib involves multiple chemical steps, beginning with 1-methyl-1H-pyrazole-4-carboxylic acid. This starting material is reacted with thionyl chloride to form the corresponding acid chloride. Subsequently, this acid chloride undergoes a reaction with 4-fluoroaniline, producing 1-methyl-4-((4-fluorophenylamino)carbonyl)-1H-pyrazole. This intermediate is then subjected to bromination, yielding 5-bromo-1-methyl-4-((4-fluorophenylamino)carbonyl)-1H-pyrazole. Further reaction with piperidine leads to 1-methyl-4-((4-fluorophenylamino)carbonyl)-5-(piperidin-1-yl)-1H-pyrazole. The final step involves reaction with 3-chloro-4-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, resulting in the formation of abrocitinib [1].
When Does Abrocitinib's Patent Protection End?
The primary patent for abrocitinib is expected to expire around 2035. However, secondary patents, such as those covering formulations or manufacturing processes, could extend market exclusivity beyond this date. DrugPatentWatch.com provides detailed patent expiry information that can be consulted for specific timelines [2].
What are the Key Competitors for Abrocitinib?
Abrocitinib, marketed as Cibinqo, is a Janus kinase (JAK) inhibitor used to treat moderate to severe atopic dermatitis. Its competitors in this therapeutic area include other JAK inhibitors like upadacitinib (Rinvoq) and abrocitinib's predecessor, baricitinib (Olumiant). Other treatment options for atopic dermatitis include topical corticosteroids, calcineurin inhibitors, and biologics such as dupilumab (Dupixent) [3].
What Are the Clinical Trial Results for Abrocitinib?
Clinical trials have demonstrated the efficacy of abrocitinib in treating moderate to severe atopic dermatitis. Studies, such as the JAK1 Real World Effectiveness (JADE) study, have shown significant improvements in skin clearance and itch reduction in patients treated with abrocitinib compared to placebo [4]. These trials have also provided data on the safety profile of the drug, identifying potential side effects [5].
What Are the Potential Risks and Side Effects of Abrocitinib?
As a JAK inhibitor, abrocitinib carries a boxed warning regarding serious infections, mortality, major cardiovascular events, and thrombosis. Other potential side effects include acne, headache, herpes simplex, and elevated creatine phosphokinase. Patients with pre-existing cardiovascular risk factors should be closely monitored [5].
Can Biosimilars of Abrocitinib Be Developed?
The development of biosimilars for abrocitinib will depend on the expiration of its primary patents. Once these patents expire, and assuming the drug is approved by regulatory agencies, biosimilar versions could potentially enter the market. The pathway for biosimilar approval involves demonstrating high similarity to the reference product in terms of quality, safety, and efficacy [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/